UroGen Pharma OverviewUroGen Pharma EBIT
EBIT (Earnings Before Interest and Taxes) analysis for URGN.
Quarterly EBIT
-$20.92M
↑ 43.34% YoY
As of Mar 31, 2026
Annual EBIT (TTM)
-$112.62M
↓ 6.77% YoY
Trailing 12 months ending Mar 31, 2026
UroGen Pharma OverviewEBIT (Earnings Before Interest and Taxes) analysis for URGN.
As of Mar 31, 2026
Trailing 12 months ending Mar 31, 2026